Stockscreener 앱 받기
8.00
0.00%
0.00
시간 외 거래:
8.00
전일 마감가:
$8.00
열려 있는:
$7.93
하루 거래량:
399.84K
Relative Volume:
0.87
시가총액:
$393.69M
수익:
$27.46M
순이익/손실:
$-46.05M
주가수익비율:
-6.2016
EPS:
-1.29
순현금흐름:
$-33.83M
1주 성능:
+11.11%
1개월 성능:
+13.64%
6개월 성능:
-7.08%
1년 성능:
+66.32%
1일 변동 폭
$7.86
$8.09
1주일 범위
$7.11
$8.10
52주 변동 폭
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
명칭
Zevra Therapeutics Inc
전화
(321) 939-3416
주소
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
ZVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.00 | 393.69M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 개시 | Guggenheim | Buy |
| 2024-09-24 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-24 | 재확인 | Maxim Group | Buy |
| 2024-04-02 | 재확인 | Maxim Group | Buy |
| 2024-03-12 | 개시 | William Blair | Outperform |
| 2023-03-17 | 개시 | Maxim Group | Buy |
모두보기
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Invesco Ltd. Has $153,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by JPMorgan Chase & Co. - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Could Be Less Than A Year Away From Profitability - simplywall.st
Are Zevra Therapeutics Inc (ZVRA) shares a good deal now? - uspostnews.com
Zevra Therapeutics to Participate in the Citizens Life Science Conference - The Manila Times
Rare Disease Leader Zevra Therapeutics Reveals Growth Strategy at Citizens Conference - Stock Titan
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Geode Capital Management LLC Has $9.91 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Investment Analysis and Advice - news.stocktradersdaily.com
Zevra calls for stockholder support against board influence bid - Investing.com
Zevra Therapeutics (ZVRA) Prepares for 2025 Annual Meeting, Advocates for Board Stability | ZVRA Stock News - GuruFocus
Zevra calls for stockholder support against board influence bid By Investing.com - Investing.com India
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders | ZVRA Stock News - GuruFocus
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - The Manila Times
Zevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest Concerns - Nasdaq
ZVRAZevra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider
Zevra Therapeutics (ZVRA) Reveals Key Insights into Niemann-Pick Type C Treatment | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewswire
Breakthrough Study Uncovers MIPLYFFA's Mechanism for Treating Fatal Genetic Disease NPC - Stock Titan
Vanguard Group Inc. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Corebridge Financial Inc. Buys 3,801 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Raymond James Financial Inc. Purchases Shares of 26,916 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Institutional investors may overlook Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) recent US$44m market cap drop as long-term gains remain positive - simplywall.st
Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher - MarketScreener
Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves - marketscreener.com
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - citybiz
$150M FDA Voucher Sale Transforms Zevra's Financial Position: Rare Disease Success Story - Stock Titan
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline - MSN
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Brokerages - Defense World
(ZVRA) Technical Data - news.stocktradersdaily.com
Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (NASDAQ:ZVRA) - Seeking Alpha
Quantbot Technologies LP Sells 7,219 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra therapeutics director Corey Watton buys $2,351 in stock By Investing.com - Investing.com Australia
Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener
Zevra Therapeutics Files Preliminary Proxy - The Manila Times
Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan
Charles Schwab Investment Management Inc. Buys 28,148 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
John Bode Bought 33% More Shares In Zevra Therapeutics - simplywall.st
Zevra Therapeutics Independent Director Acquires 33% More Stock - Yahoo Finance
Insider Buying: John Bode Acquires Additional Shares of Zevra Th - GuruFocus
Zevra therapeutics director Bode acquires $79,624 in stock By Investing.com - Investing.com Canada
Zevra therapeutics director Bode acquires $79,624 in stock - Investing.com
ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView
Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Australia
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus By Investing.com - Investing.com South Africa
HC Wainwright Predicts Lower Earnings for Zevra Therapeutics - Defense World
Zevra Therapeutics Inc (ZVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):